Designing safer opioids

Opioid medications tap into the body’s natural system for mitigating pain by activating pain-suppressing opioid receptors on nerve cells in the brain. Although the drugs are intended to help people, sometimes these medications lead to harm. People who take opioids can become physically dependent on them, where sudden stopping can produce withdrawal symptoms, such as muscle pain, nausea and vomiting. In addition, opioids make breathing slow and shallow, a side effect that can become fatal.

Attempts to design safer opioids have largely focused on identifying molecules that bind to the same spot on the receptor, known as the active site, where the body’s own pain-relieving signals attach. In an earlier study, researchers found a molecule called C6 guano, which can activate the opioid receptor when it binds outside the active site. C6 guano interacts with a location inside the opioid receptor that typically responds to sodium ions. Despite its promising effects, C6 guano has a significant drawback: It cannot pass through the blood-brain barrier that protects the organ. So, a team led by Susruta Majumdar, Jay McLaughlin, Haoqing Wang and Ruth Huttenhain set out to improve upon this discovery by identifying a similar molecule with the potential to travel from the blood stream to opioid receptors in the brain.

To find an alternative that also binds to the opioid receptor, the researchers synthesized and evaluated 10 compounds with chemistry that might enable passage through the blood-brain barrier. During their initial testing in cells, they identified the most promising candidate derived from fentanyl, called RO76. By capturing molecules in proximity of the activated receptor, the team showed that RO76 produces a signal within cells that differs from those initiated by classic opioids, such as morphine.

They then evaluated the compound’s efficacy in mice. In these experiments, RO76 appeared to suppress pain as effectively as morphine. But when comparing the opioids’ effects on the animals breathing rates, they found that RO76 slowed breathing far less, suggesting it may not be as deadly as morphine. Likewise, when they gave the mice an opioid-blocking medication, the mice chronically taking RO76 experienced fewer withdrawal symptoms than those taking morphine. What’s more, the team found that, when given by mouth, the new fentanyl derivative had similar, if slightly lower, pain-suppressing effects than when injected under the skin of the animals. The researchers say these results suggest RO76 has the potential for development as an oral medication for humans.

The authors acknowledge funding from the National Institutes of Health and the Pharmaceutical Research and Manufacturers of America Postdoctoral Fellowships. Two of the authors also acknowledge financial interests with biopharmaceutical companies.